Recombinant Human CD40 ligand (CD40LG)

What is CD40 Ligand and what is its physiological role?

CD40 Ligand (CD40LG), also known as CD154, gp39, or TNFSF5, is a type II transmembrane glycoprotein belonging to the TNF superfamily. It is primarily expressed on the surface of activated T cells, where it plays several critical roles in immune function:

• CD40LG binds to CD40 receptors on B cells, triggering B cell proliferation, germinal center formation, immunoglobulin class switching, and antibody production

• It regulates interactions between T cells and antigen-presenting cells (APCs)

• It stimulates cytokine production and tumoricidal activity in peripheral blood monocytes

• It co-stimulates proliferation of activated T cells, accompanied by the production of IFN-gamma, TNF-alpha, and IL-2

The CD40-CD40LG interaction is essential for both humoral and cellular immune responses. Without this interaction, B cells cannot undergo normal immunoglobulin class switching from IgM to other isotypes (IgG, IgA, IgE), leading to impaired adaptive immunity .

How is CD40LG structured and where is it expressed?

CD40LG is a 261 amino acid glycoprotein that exists in both membrane-bound and soluble trimeric forms, both of which are bioactive. The protein's active domain spans amino acids 108-261 in humans .

Expression patterns:

• Primarily expressed on activated CD4+ T cells

• Stored preformed in secretory lysosomes in effector and memory T helper 1 (Th1) cells

• Can be rapidly mobilized to the cell surface upon T cell activation before new protein synthesis

• May also be expressed at lower levels on other cell types, including platelets, monocytes, and some endothelial cells

The rapid mobilization of preformed CD40LG from intracellular compartments in memory and effector T cells provides a mechanism for these cells to execute their functions quickly upon antigen recognition .

What are the key genetic aspects of human CD40LG?

The human CD40LG gene:

• Is located on the X chromosome (hence X-linked inheritance patterns of CD40LG deficiency)

• Has the official symbol CD40LG (previously known as TNFSF5, HIGM1, and IMD3)

• Has Gene ID 959

• Is mapped to locus Xq26.3

• Contains 5 exons

Mutations in the CD40LG gene cause X-linked hyper-IgM syndrome (HIGM1), characterized by normal or elevated IgM levels but absent or severely decreased IgG, IgA, and IgE levels . More than 150 different mutations in the CD40LG gene have been identified that can cause this condition .

How is recombinant human CD40LG produced for research applications?

Recombinant human CD40LG (rhuCD40LG) can be produced using several expression systems, each with different characteristics:

For GMP-grade production, HEK293 expression systems are commonly used with animal component-free processes. The resulting protein should have:

• Residual host cell DNA content <10pg/mg

• Residual host cell protein content <1μg/mg

• Endotoxin levels <0.1EU/μg

• Purity greater than 95% as determined by reducing SDS-PAGE

What are the key quality control parameters for recombinant CD40LG?

When characterizing recombinant CD40LG for research use, several quality control parameters should be assessed:

• Bioactivity assays: In functional ELISA assays, recombinant human CD40LG should bind to CD40/TNFRSF5 with an ED50 in the range of 0.300-3.60 ng/mL

• Purity assessment:

  • SDS-PAGE under reducing conditions should show a single band at approximately 18 kDa

  • Purity should be >95% by SDS-PAGE

• Endotoxin testing: Levels should be <0.1EU/μg for research applications and even lower for clinical-grade material

• Functional testing: Verification of ability to stimulate B-cell proliferation and induce cytokine production in monocytes

• Stability assessment: Testing protein stability under different storage conditions, with recommended storage at -80°C after reconstitution with aliquoting to minimize freeze-thaw cycles

The recommended working concentration for most in vitro applications ranges from 100-1000ng/ml .

What are the key differences between various forms of recombinant CD40LG?

Researchers should be aware of important differences between various recombinant CD40LG formulations:

The soluble form of CD40LG has been shown to effectively inhibit human breast carcinoma growth both in vitro and in vivo, offering significant advantages over using monoclonal antibodies against CD40 . When selecting a recombinant form, researchers should consider the specific application and desired signaling strength.

How can recombinant CD40LG be used to study B cell activation and antibody production?

Recombinant CD40LG is a powerful tool for studying B cell function, particularly for:

Experimental protocol for B cell activation:

• Isolate primary B cells from peripheral blood or splenocytes

• Culture autologous B cells (4 × 10^5 cells/100 μl) with T cells or recombinant CD40LG

• For T-cell-independent activation with rCD40LG: Use 0.1-1 μg/ml of recombinant CD40LG

• For comparison studies, include control conditions:

  • B cells alone (negative control)

  • B cells + LPS (T-cell-independent positive control)

  • B cells + LPS + anti-CD40LG (blocking control)

• Culture in RPMI 1640/10% FBS at 37°C/5% CO2 for 4-8 days

• Supplement 50 μl fresh media at day 4

• Harvest supernatants for antibody quantification by ELISA

Readouts to assess B cell activation:

• Flow cytometry for activation markers (CD25, CD69) and plasma cell marker CD138

• ELISA for antibody production (IgM, IgG, IgA)

• qPCR for gene expression changes

This approach allows researchers to isolate the specific effects of CD40LG-CD40 interaction from other T-cell-derived signals and has been instrumental in understanding B cell class switching mechanisms .

What protocols are recommended for using CD40LG in immunological assays?

Protocol for CD40LG-mediated T cell activation assessment:

• T cell isolation and preparation:

  • Isolate CD4+ T cells from peripheral blood mononuclear cells

  • For preformed CD40LG assessment: Differentiate T cells into Th1 effector cells in vitro for 5-7 days with IL-12 and anti-IL-4

• Stimulation:

  • Option A (TCR stimulation): Stimulate with anti-CD3/CD28 antibodies or PMA/ionomycin

  • Option B (Antigen-specific): Use peptide-loaded antigen-presenting cells

• Blocking controls:

  • Include anti-CD40LG blocking antibody (1 μg/ml) to confirm specificity

  • Use isotype control IgG1 as negative control

• Analysis of preformed CD40LG versus de novo synthesis:

  • To block protein synthesis: Pretreat cells with cycloheximide (10 μg/mL) for 1 hour before stimulation

  • Stain for surface CD40LG at early time points (0-2 hours) to detect mobilization of preformed protein

  • Stain at later time points (4-24 hours) to detect newly synthesized protein

• Flow cytometry assessment:

  • Surface staining: 2 μg/mL of PE-anti-CD40L mAb for surface expression

  • Intracellular staining: Fix cells, then stain with anti-CD40L using Cytofix/Cytoperm kit

This protocol allows discrimination between rapid mobilization of preformed CD40LG in memory T cells versus delayed expression in naive T cells .

How can recombinant CD40LG be used in cancer research models?

Recombinant CD40LG has shown promising applications in cancer research:

In vitro protocol for tumor cell growth inhibition:

• Confirm CD40 expression on tumor cell lines by flow cytometry

• Enhance CD40 expression with interferon-γ pretreatment if needed

• Incubate CD40+ tumor cells with soluble recombinant human CD40LG at varying concentrations

• Assess proliferation inhibition via:

  • MTT/MTS assays for metabolic activity

  • BrdU incorporation for DNA synthesis

  • Flow cytometry for cell cycle analysis

• Evaluate apoptosis induction using:

  • Annexin V/PI staining

  • TUNEL assay for DNA fragmentation

In vivo xenograft model protocol:

• Implant CD40+ human tumor cells (e.g., breast carcinoma) in immunodeficient mice

• Administer recombinant human CD40LG subcutaneously daily for 5 days

• Optimal dosing based on phase I clinical data: 0.1 mg/kg/day (maximum tolerated dose)

• Monitor tumor growth and survival outcomes

This approach has demonstrated significant survival increases in xenograft models and has led to instances of complete tumor remission in clinical settings .

How does preformed CD40LG in T cells contribute to rapid immune responses?

Recent research has revealed that CD40LG exists in a preformed state within secretory lysosomes of effector and memory Th1 cells, allowing for rapid immune responses:

• Storage mechanism:

  • Preformed CD40LG is stored in secretory lysosomes (SLs)

  • It colocalizes more strongly with FasL than with CTLA-4 within these compartments

• Mobilization dynamics:

  • Upon T cell receptor (TCR) stimulation, these SLs rapidly mobilize to the cell surface

  • Surface expression occurs within minutes, before new protein synthesis

  • This can be demonstrated experimentally by pretreating cells with cycloheximide (CHX) to block protein synthesis before stimulation

• Cell type specificity:

  • This mechanism is a general property of effector and memory Th1 cells

  • It occurs in both in vitro-generated and in vivo-derived cells

  • Naive CD4+ T cells contain intracellular CD40LG but cannot rapidly mobilize it to the surface

• Functional significance:

  • Provides a mechanism for rapid execution of T cell effector functions

  • Allows for immediate help to B cells and other CD40-expressing cells

  • Particularly important for memory responses to previously encountered antigens

This system enables memory T cells to rapidly deliver CD40L to APCs upon antigen recognition, providing immediate stimulation before new protein synthesis occurs, thus accelerating the secondary immune response .

What is the role of CD40LG in T cell-intrinsic signaling?

Beyond its well-established role in activating CD40-expressing cells, CD40LG also mediates important intrinsic signaling within T cells themselves:

• Bidirectional signaling model:

  • CD40L can initiate signal transduction within the CD40L-expressing T cell

  • This "reverse signaling" contributes to optimal T cell function

• Experimental evidence:

  • Stimulation of CD40L by soluble CD40 in CD40−/− mouse models restores:

    • Initiation of germinal center formation

    • Optimal production of IL-4 by T cells

  • This demonstrates that CD40L signaling enhances T cell function independent of CD40 expression on target cells

• Molecular mechanisms:

  • CD40L engagement activates protein tyrosine kinases

  • May involve interaction with other T cell surface molecules

  • Leads to enhanced cytokine production and T cell proliferation

• Functional significance:

  • CD40L-deficient T cells from X-linked hyper-IgM syndrome patients show impaired cytokine production

  • These defects cannot be fully restored by providing normal APCs

  • Suggests intrinsic signaling defects in CD40L-deficient T cells

This bidirectional signaling model explains why CD40L deficiency impacts T cell functions beyond the mere inability to activate CD40-expressing cells and has implications for therapeutic approaches targeting this pathway .

What mechanisms contribute to CD40LG-mediated tumor inhibition?

The antitumor effects of recombinant CD40LG operate through multiple complementary mechanisms:

• Direct mechanisms on CD40+ tumor cells:

  • Induction of apoptosis through activation of caspase pathways

  • Cell cycle arrest in G0/G1 phase

  • Increased sensitivity to conventional chemotherapeutics

  • These effects are enhanced by interferon-γ, which increases CD40 expression

• Immune-mediated mechanisms:

  • Enhanced antigen presentation by dendritic cells

  • Activation of tumor-infiltrating macrophages

  • Promotion of tumor-specific T cell responses

  • Breaking tumor-induced immune tolerance

• Vascular effects:

  • Potential anti-angiogenic activity

  • Modulation of tumor microenvironment

Analysis of clinical responses to recombinant human CD40LG in phase I trials showed:

• 6% partial response rate (one laryngeal carcinoma, one NHL)

• Long-term complete remission in one patient with laryngeal cancer

• 38% stable disease rate after one course

• Sustained disease stabilization in 4 patients through four courses

These findings suggest that CD40LG therapy works through both direct tumor cell killing and enhancement of anti-tumor immunity, making it a promising candidate for combination immunotherapy approaches .

What is the current status of recombinant CD40LG in clinical trials?

Recombinant human CD40LG has been evaluated in clinical settings:

Phase I clinical trial results:

• 32 patients with advanced solid tumors or intermediate/high-grade non-Hodgkin's lymphoma

• Three dose levels tested: 0.05, 0.10, and 0.15 mg/kg/day

• Administration: Subcutaneous, daily for 5 days

• Total of 65 courses administered

• Maximum tolerated dose (MTD): 0.1 mg/kg/day

• Dose-limiting toxicity: Transient elevations of serum liver transaminases

• Pharmacokinetics: Half-life of 24.8 ± 22.8 hours at the MTD

Clinical outcomes:

• 6% partial response rate

• One remarkable case: patient with laryngeal cancer showed partial response sustained for 12 months, then complete response after discontinuation, remaining disease-free at 24 months follow-up

• 38% stable disease after one course

• 13% (4 patients) maintained stable disease through four courses

How does CD40LG deficiency manifest and what are the implications for therapy?

CD40LG deficiency leads to X-linked hyper-IgM syndrome (HIGM1), with significant immunological consequences:

Clinical and laboratory features:

• Normal or elevated IgM levels

• Severely decreased or absent IgG, IgA, and IgE

• Recurrent bacterial infections beginning in infancy

• Opportunistic infections (particularly Pneumocystis jirovecii)

• Neutropenia in approximately 50% of patients

• Increased risk of autoimmune disorders and malignancies

Molecular basis:

• More than 150 different mutations in the CD40LG gene identified

• Mutations lead to:

  • Production of abnormal CD40LG protein

  • Complete absence of CD40LG expression

  • Inability of CD40LG to bind CD40

Therapeutic approaches:

• Supportive care:

  • Immunoglobulin replacement therapy

  • Prophylactic antibiotics

• Definitive treatment:

  • Hematopoietic stem cell transplantation (HSCT)

  • Potential future gene therapy approaches

• Experimental approaches:

  • Recombinant CD40LG protein therapy

  • Gene-corrected autologous T cells

This condition provides a "human knockout" model that has been instrumental in understanding CD40LG biology and developing therapeutic strategies for other immune disorders .

What are the potential toxicities and limitations of recombinant CD40LG therapy?

Clinical studies have identified important considerations regarding recombinant CD40LG safety:

Dose-related toxicities:

• Hepatotoxicity: Transient elevations of serum liver transaminases are the dose-limiting toxicity

  • Grade 3/4 transaminase elevations occurred in:

    • 14% of patients at 0.05 mg/kg/day

    • 28% of patients at 0.10 mg/kg/day

    • 57% of patients at 0.15 mg/kg/day

  • These elevations were transient and reversible

• Other toxicities: Generally mild to moderate, including:

  • Injection site reactions

  • Fatigue

  • Low-grade fever

Limitations and considerations:

• Potential immune overstimulation:

  • Risk of systemic inflammatory responses

  • Potential for autoimmune phenomena

  • Cytokine release syndrome

• Delivery and pharmacokinetic challenges:

  • Short half-life (24.8 ± 22.8 hours)

  • Need for repeated dosing

  • Limited tissue penetration

• Target specificity:

  • CD40 is expressed on many normal cells

  • Potential for off-target effects on non-tumor tissues

  • Differential activity in species (human ligand has lower affinity for murine CD40)

Despite these challenges, the manageable safety profile and encouraging clinical responses suggest that optimized dosing regimens and potential combination approaches merit further investigation .

What are the optimal storage and handling conditions for recombinant CD40LG?

Proper handling of recombinant CD40LG is critical for maintaining its biological activity:

Storage recommendations:

• Store lyophilized protein at -80°C

• After reconstitution, store at -80°C

• Aliquot the reconstituted solution to minimize freeze-thaw cycles

• Avoid more than 2-3 freeze-thaw cycles

Reconstitution guidelines:

• Always centrifuge tubes before opening

• Do not mix by vortex or pipetting

• Not recommended to reconstitute to a concentration >100μg/ml

• Dissolve lyophilized protein in sterile distilled water or appropriate buffer

Working concentration ranges:

• In vitro cell culture: 100-1000 ng/ml

• Receptor binding assays: 0.300-3.60 ng/ml

• In vivo studies: 0.05-0.10 mg/kg/day (based on clinical MTD)

Stability considerations:

• Activity may decrease over time even at -80°C

• Include functional controls in each experiment

• Verify activity periodically with binding or functional assays

Following these guidelines will help ensure experimental reproducibility and valid research outcomes when working with recombinant CD40LG.

How can CD40LG-CD40 interactions be effectively blocked in experimental systems?

For mechanistic studies, researchers often need to block CD40LG-CD40 interactions:

Blocking strategies:

• Anti-CD40LG monoclonal antibodies:

  • Optimal concentration: 1 μg/ml for in vitro culture systems

  • Include isotype control IgG1 at the same concentration

  • Validate blocking efficiency using a functional readout (e.g., B cell activation)

• Soluble CD40 receptor:

  • Recombinant CD40-Fc fusion proteins

  • Acts as a competitive inhibitor of membrane CD40

  • Typical working concentration: 1-10 μg/ml

• Small molecule inhibitors:

  • Target specific interaction domains

  • Less commonly used than antibodies

  • May have higher specificity for certain signaling pathways

• Gene silencing approaches:

  • siRNA or CRISPR-based knockdown/knockout of CD40 or CD40LG

  • Provides more complete inhibition but requires genetic manipulation

Experimental validation:

• Flow cytometry to confirm blocking of surface binding

• Functional assays (e.g., B cell activation, antibody production)

• Positive and negative controls to confirm specificity

These approaches provide valuable tools for dissecting the precise contribution of CD40LG-CD40 interactions in complex biological systems.

How can researchers optimize transfection of CD40LG for functional studies?

For CD40LG overexpression studies in primary cells or cell lines:

Optimized transfection protocol:

• Plasmid preparation:

  • Clone CD40LG cDNA into expression vectors (e.g., pEGFP-C1)

  • Include appropriate tags for detection if needed

  • Prepare endotoxin-free plasmid at high concentration (1-2 μg/μl)

• Transfection methods for primary T cells:

  • Nucleofection (Amaxa/Lonza) shows highest efficiency

  • Typical conditions: 5 μg plasmid per 5 × 10^6 cells

  • Programs: Human T cell nucleofector kit, program U-014

  • Expected efficiency: ≥40% with GFP reporter

• Verification of expression:

  • Flow cytometry using fluorochrome-conjugated anti-CD40LG antibody

  • Western blotting for total protein expression

  • RT-qPCR for mRNA levels

• Functional validation:

  • Co-culture transfected T cells with B cells (1:1 ratio)

  • Assess B cell activation (CD25, CD69 expression)

  • Measure plasma cell differentiation (CD138 expression)

  • Quantify antibody production in supernatants

This approach enables mechanistic studies of CD40LG function independent of other T cell activation signals and has been instrumental in demonstrating the sufficiency of CD40LG overexpression for driving B cell differentiation .